Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GKL-006 + TACE vs TACE alone in unresectable hepatocellular carcinoma
NCT07209813Phase 2Recruiting
- Sponsor
- GenePlus
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of GKL-006 in hepatocellular carcinoma (HCC), sponsored by GenePlus. Started Nov 2025; status: recruiting.
02
Drugs
GKL-006
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07209813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209813.